Plain-English translation of NCT06940011 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether Endocalyx, a food supplement, can help lower blood pressure in people whose high blood pressure remains difficult to control even while taking three or more blood pressure medications. Researchers want to see if this treatment can improve blood pressure readings and the health of tiny blood vessels. You would receive either the medication or a placebo (a pill with no active ingredient) for 12 weeks.
Some people's high blood pressure does not respond well to standard medications, which puts them at higher risk for heart disease and stroke. This study is exploring whether this medication might help people whose blood pressure remains stubbornly high despite being on multiple drugs.
You likely qualify if…
You likely don't qualify if…
You would visit the research center at baseline and then return for follow-up visits during the 12-week study period. Each day, you would take 4 capsules of either the medication or placebo—you can split them into two doses (morning and afternoon) or take all 4 in the morning, whichever works best for you. The research team will check your blood pressure multiple times, including at home with a 24-hour monitor, and may perform special tests to look at the health of your small blood vessels. They will also ask you questions about your quality of life and how you're feeling.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Netherlands
Phase
Testing effectiveness
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
Dutch Heart Foundation, Dutch Kidney Foundation
Enrollment target
~64 participants
Started
January 2025
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rik Olde Engberink, MD PhD
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.